NCT06186440View on ClinicalTrials.gov

Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

January 1, 2025

Conditions

Glioblastoma Multiforme of Brain

Interventions

DRUG

Cisplatin Plus Temozolomide

Cisplatin Plus Temozolomide . Cisplatin 20mg/mCisplatin days 1-5

DRUG

Temozolomide

All Listed Sponsors

lead

Zhongnan Hospital

OTHER

NCT06186440 - Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma | Biotech Hunter | Biotech Hunter